Introduction {#tca13059-sec-0005}
============

Thymic epithelial tumors are common within the anterior mediastinum, and can be classified histologically into thymomas and thymic carcinomas.[1](#tca13059-bib-0001){ref-type="ref"}, [2](#tca13059-bib-0002){ref-type="ref"} Based on primary tumor extension and the degree of involvement of the surrounding organs, the Masaoka--Koga staging system has been widely accepted for thymomas and thymic carcinomas.[3](#tca13059-bib-0003){ref-type="ref"} Several survival predictors for thymomas have been proposed. Li *et al.* reported that age and Masaoka--Koga stage were prognostic factors for thymomas.[4](#tca13059-bib-0004){ref-type="ref"} Similarly, Mou *et al.* concluded that age, Masaoka--Koga stage, and postoperative radiation were prognostic factors for thymomas;[5](#tca13059-bib-0005){ref-type="ref"} however, Yanagiya *et al.* demonstrated that age and histological type rather than Masaoka--Koga stage were meaningful prognostic factors.[6](#tca13059-bib-0006){ref-type="ref"} To date, large‐scale studies on the prognostic factors of thymomas have been limited and the reported associations have not been confirmed.

Nomography has been widely used to predict the survival of cancer patients;[7](#tca13059-bib-0007){ref-type="ref"} however, nomography for thymomas has not yet been developed. In this study we used data from the population‐based Surveillance, Epidemiology, and End Results (SEER) database to clarify the prognostic indicators from which a nomogram for thymomas was created and validated in an independent validation cohort from our own databases. We anticipate that our results will improve our understanding of thymomas and optimize individual therapy and follow‐up.

Methods {#tca13059-sec-0006}
=======

Ethics statement {#tca13059-sec-0007}
----------------

This study was conducted with approval from the Ethics Committee of Zhongshan Hospital, Fudan University, Shanghai, China. The data accessed from the SEER database was freely available. All work conformed to the provisions of the Declaration of Helsinki. The Ethics Committee of Zhongshan Hospital, Fudan University, Shanghai, China exempted the requirement for written informed consent.

Patients {#tca13059-sec-0008}
--------

The training cohort was obtained from the SEER 18 Registry, including Hurricane Katrina‐impacted cases ([www.seer.cancer.gov](http://www.seer.cancer.gov); SEER\*Stat version 8.3.5, Database: Incidence -- SEER 18 Regs Custom Data \[with additional treatment fields\], Nov 2016 Sub \[1973--2014 varying\] -- Linked To County Attributes -- Total US, 1969--2015 Counties).

Patients in which the thymus was the primary site were selected using the variable, "primary site" (thymus = 379).[8](#tca13059-bib-0008){ref-type="ref"} Patients with thymomas were identified by histology (International Classification of Diseases codes 8580--8585).[9](#tca13059-bib-0009){ref-type="ref"} Patients were included in the study if: they had been diagnosed with microscopic confirmation by histology or cytology; and underwent simple or partial, total, radical, and debulking surgery. Patients were excluded for the following reasons: if the primary reporting source was an autopsy, death certificate, nursing home, or hospice; they were diagnosed at \< 18 years of age; with a survival duration of ≤ 3 months (to eliminate perioperative mortality);[10](#tca13059-bib-0010){ref-type="ref"} administered radiotherapy prior to surgery, before and after surgery, or had an unknown treatment sequence with surgery; and diagnosed before 1983 (because of insufficient surgical data) (Fig [1](#tca13059-fig-0001){ref-type="fig"}). Patients who had undergone cancer‐related surgery were identified as "surgery performed" in the variable, "reason: no cancer‐directed surgery."

![A flow diagram of the selection process for the study cohort. International Classification of Diseases‐O‐3 histology codes: 8580--8585.](TCA-10-1167-g001){#tca13059-fig-0001}

Patients were staged according to the Masaoka--Koga staging system: I/IIA, invasive tumor confined to gland of origin or localized, not otherwise specified; IIB adjacent connective tissue; III/IV adjacent organs/structures, further contiguous extension, or any positive lymph nodes; and unknown, unknown extent of disease.[9](#tca13059-bib-0009){ref-type="ref"}

Patients in the validation cohort were selected from the Department of Thoracic Surgery, Zhongshan Hospital, Fudan University using the same inclusion and exclusion criteria as for the training cohort. Specifically, 192 thymoma patients between 2004 and 2013 with complete survival data were included. All patients were Chinese Han, with an unknown tumor grade. As for the surgical type, in patients with myasthenia gravis, the thymus and bilateral pericardial fat pad were resected and peripheral adipose tissue were swept, which corresponded to radical surgery in the SEER database. Total thymectomy was performed in most patients without myasthenia gravis, which meant the total removal of the thymus. Partial thymectomy could be performed in patients with early stage and small tumors, which meant the removal of tumor rather than the entire thymus. Debulking surgery was performed with the removal of the thymus and adjacent resectable organs if the great vessels had been invaded.

Statistical analysis {#tca13059-sec-0009}
--------------------

The clinicopathological variables were categorized. Survival duration was defined as the date of diagnosis to the date of death or the end of the study. The Kaplan--Meier method was used to estimate overall survival (OS), with the log‐rank test for significance. Univariate and multivariate Cox proportional hazards regression analysis were performed to identify the independent prognostic factors. Related clinicopathological factors with *P* \< 0.05 on univariate analyses were adjusted. All statistical analyses were performed using SPSS version 24. All tests were two‐sided and *P* \< 0.05 was considered significant.

Construction and validation of the nomogram {#tca13059-sec-0010}
-------------------------------------------

A nomogram was built using the rms package in R version 3.4.4 (<http://www.r-project.org/>). The maximum score of each variable was set at 10. The nomogram was measured based on the Harrel concordance index (C‐index). The nomogram was also evaluated by comparing nomogram‐predicted and observed Kaplan--Meier estimates of survival probability. Bootstraps of 1000 resamples were set and calibration curves were calculated by regression analysis.[11](#tca13059-bib-0011){ref-type="ref"}

Similarly, the C‐indices and 95% confidence intervals (CIs) were calculated to evaluate the performance of the nomogram. The calibration plot that described the fitting degree between actual and nomogram‐predicted survival was constructed in the validation cohort.

Results {#tca13059-sec-0011}
=======

Patient characteristics {#tca13059-sec-0012}
-----------------------

Of the 5515 patients with thymic malignancies between 1983 and 2014, 3530 (64.0%) were diagnosed with thymomas. Among them, 1312 (23.8%) patients who met the inclusion criteria were enrolled in the training cohort. In addition, 192 patients with thymomas between 2004 and 2013 from our center were included in the validation cohort. Their demographic characteristics are listed in Table [1](#tca13059-tbl-0001){ref-type="table"}. Of the 1312 patients, 667 (50.8%) were female; the median age was 55 (range: 18--91) years; 618 (47.1%) patients were Masaoka--Koga stage III/IV; and 735 (56.0%) and 298 (22.7%) patients were administered postoperative radiation and chemotherapy, respectively. Of note, the SEER database did not include variables to identify the sequence of surgery and chemotherapy or to elucidate the medications used in chemotherapy. Of the 1312 patients, there were 1160 (88.4%) and 524 (39.9%) with an unknown tumor grade and histology, respectively.

###### 

Characteristics of thymoma patients in each cohort

                             Training cohort   Validation cohort         
  -------------------------- ----------------- ------------------- ----- ------
  Size (cm)                                                              
  Median (range)             6.6 (0.3--24.0)   6.0 (0.7--17.0)           
  \< 6.6                     565               43.1                91    47.4
  ≥ 6.6                      569               43.3                85    44.3
  Unknown                    178               13.6                16    8.3
  Age                                                                    
  \< 40 years                218               16.6                30    15.6
  40--49 years               263               20.1                48    25.0
  50--59 years               311               23.7                62    32.3
  60--69 years               301               22.9                40    20.8
  ≥ 70 years                 219               16.7                12    6.3
  Gender                                                                 
  Male                       645               49.2                107   55.7
  Female                     667               50.8                85    44.3
  Race                                                                   
  White                      869               66.2                      
  Black                      179               13.7                      
  Other/Unknown              264               20.1                      
  Marital status                                                         
  Married                    808               61.6                175   91.1
  Not married                449               34.2                17    8.9
  Unknown                    55                4.2                 0     0
  PORT                                                                   
  Yes                        735               56.0                24    12.5
  No                         577               44.0                168   87.5
  Chemotherapy                                                           
  Yes                        298               22.7                10    5.2
  No                         1014              77.3                182   94.8
  Grade                                                                  
  I                          81                6.2                       
  II                         20                1.5                       
  III                        40                3.0                       
  IV                         11                0.8                       
  Unknown                    1160              88.5                      
  Histology                                                              
  A                          89                6.8                 15    7.8
  AB                         185               14.1                27    14.1
  B1                         150               11.4                21    10.9
  B2                         158               12.1                77    40.1
  B3                         206               15.7                31    16.2
  Not otherwise specified    524               39.9                21    10.9
  Masaoka--Koga stage                                                    
  I/IIA                      403               30.7                90    46.9
  IIB                        260               19.8                16    8.3
  III/IV                     618               47.1                57    29.7
  Unknown                    31                2.4                 29    15.1
  Surgery type                                                           
  Total resection            553               42.1                96    50.0
  Simple/partial resection   403               30.7                50    26.0
  Radical surgery            308               23.5                39    20.3
  Debulking surgery          48                3.7                 7     3.7
  Cause of death                                                         
  Alive                      948               72.2                175   91.1
  Cancer death               170               13.0                8     4.2
  Non‐cancer death           194               14.8                9     4.7

PORT, postoperative radiotherapy.

Survival analysis {#tca13059-sec-0013}
-----------------

The median follow‐up duration was 68 (range: 4--304) months and 93 (range: 12--162) months in the training and validation cohorts, respectively. The median survival duration was 182 months and the five‐year OS rates were 83.8% and 92.6% in the training and validation cohorts, respectively.

Univariate analysis showed that age (*P* \< 0.01), size (*P* \< 0.01), marital status (*P* = 0.032), histology (*P* \< 0.01), Masaoka--Koga stage (*P* \< 0.01), chemotherapy (*P* \< 0.01), and surgery type (*P* \< 0.01) were significant prognostic factors of OS (Table [2](#tca13059-tbl-0002){ref-type="table"}). Related clinicopathological factors with *P* values \< 0.05 in the univariate analyses were adjusted for multivariate analysis. After multivariate analysis, only age (*P* \< 0.01), size (*P* \< 0.01), Masaoka--Koga stage (*P* \< 0.01), chemotherapy (*P* = 0.011), and surgery type (*P* = 0.033) remained independent prognostic factors of OS (Table [2](#tca13059-tbl-0002){ref-type="table"}). Of note, grade was not a prognostic factor of OS. Young age, small tumors, early‐stage tumors, no chemotherapy, or total resection were factors of significantly better OS (Fig [2](#tca13059-fig-0002){ref-type="fig"}).

###### 

Univariate and multivariate analysis of overall survival in the training cohort

                                    Univariate   *P*            Multivariate                                          *P*                        
  --------------------------------- ------------ -------------- ----------------------------------------------------- ----------- -------------- -----------------------------------------------------
  Age                                                           \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  \< 40 years                       Reference                                                                         Reference                  
  40--49 years                      0.938        0.639--1.375   0.742                                                 1.019       0.691--1.503   0.923
  50--59 years                      1.125        0.781--1.620   0.527                                                 1.290       0.890--1.870   0.179
  60--69 years                      1.818        1.282--2.580   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   2.148       1.504--3.068   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  ≥ 70 years                        3.688        2.619--5.193   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   4.387       3.080--6.249   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  Size                                                          \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  \< 6.6                            Reference                                                                         Reference                  
  ≥ 6.6                             1.465        1.153--1.862   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   1.280       0.996--1.644   0.054
  Unknown                           2.218        1.681--2.927   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   1.945       1.457--2.596   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  Gender                                                        0.050                                                                            
  Male                              Reference                                                                                                    
  Female                            1.229        1.000--1.511   0.050                                                                            
  Race                                                          0.951                                                                            
  White                             Reference                                                                                                    
  Black                             0.984        0.725--1.334   0.915                                                                            
  Other/Unknown                     0.959        0.739--1.245   0.754                                                                            
  Marital status                                                0.032[**\***](#tca13059-note-0003){ref-type="fn"}                                0.197
  Married                           Reference                                                                         Reference                  
  Not married                       1.288        1.041--1.594   0.020[**\***](#tca13059-note-0003){ref-type="fn"}     1.106       0.891--1.374   0.361
  Unknown                           0.724        0.357--1.467   0.370                                                 0.597       0.293--1.216   0.155
  Grade                                                         0.067                                                                            
  I                                 Reference                                                                                                    
  II                                0.949        0.354--2.542   0.917                                                                            
  III                               2.100        1.102--4.001   0.024[**\***](#tca13059-note-0003){ref-type="fn"}                                
  IV                                1.975        0.788--4.948   0.146                                                                            
  Unknown                           1.135        0.714--1.803   0.593                                                                            
  Histology                                                     \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              0.441
  A                                 0.924        0.549--1.558   0.768                                                 0.992       0.580--1.696   0.977
  AB                                0.716        0.454--1.130   0.151                                                 0.908       0.570--1.444   0.682
  B1                                0.759        0.476--1.209   0.246                                                 0.878       0.549--1.405   0.588
  B2                                0.595        0.353--1.003   0.051                                                 0.837       0.493--1.423   0.512
  B3                                Reference                                                                         Reference                  
  NOS                               1.144        0.832--1.571   0.407                                                 1.178       0.851--1.631   0.324
  Masaoka--Koga stage                                           \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  I--IIA                            0.304        0.226--0.410   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   0.366       0.267--0.502   \<0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  IIB                               0.440        0.324--0.598   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   0.563       0.406--0.780   \<0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  III--IV                           Reference                                                                         Reference                  
  Unknown                           0.789        0.468--1.329   0.373                                                 0.608       0.356--1.040   0.069
  PORT                                                          0.590                                                                            
  Yes                               Reference                                                                                                    
  No                                1.060        0.858--1.308   0.590                                                                            
  Chemotherapy                                                  \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              0.011[**\***](#tca13059-note-0003){ref-type="fn"}
  Yes                               Reference                                                                         Reference                  
  No                                0.608        0.484--0.764   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   0.720       0.560--0.926   0.011[**\***](#tca13059-note-0003){ref-type="fn"}
  Surgery type                                                  \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}                              0.033[**\***](#tca13059-note-0003){ref-type="fn"}
  Total surgical removal            Reference                                                                         Reference                  
  Simple/partial surgical removal   1.688        1.289--2.210   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   1.476       1.115--1.954   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}
  Radical surgery                   2.240        1.703--2.946   \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   1.449       1.082--1.941   0.013[**\***](#tca13059-note-0003){ref-type="fn"}
  Debulking                         2.531        1.574‐4.071    \< 0.01[**\***](#tca13059-note-0003){ref-type="fn"}   1.435       0.865--2.381   0.162

Indicates *P* \< 0.05. CI, confidence interval; HR, hazard ratio; NOS, not otherwise specified; PORT, postoperative radiotherapy.

![Overall Kaplan--Meier survival curves according to (**a**) age, (**b**) tumor size, (**c**) chemotherapy, (**d**) surgery type, and (**e**) Masaoka--Koga stage.](TCA-10-1167-g002){#tca13059-fig-0002}

Establishment and validation of the nomogram {#tca13059-sec-0014}
--------------------------------------------

A nomogram for OS was established according to multivariate analysis (Fig [3](#tca13059-fig-0003){ref-type="fig"}). To estimate the 5 and 10‐year OS rates, we identified the score for each factor based on the point scale at the top of the nomogram and the sum of the points for each factor. We then estimated the 5 and 10‐year OS rates based on the bottom point scale of the nomogram. The calibration plot based on bootstrap resampling validation demonstrated good agreement between predicted and actual survival (Fig [4](#tca13059-fig-0004){ref-type="fig"}). In the bootstrap resampling cohort, the C‐indices were 0.713 (95% CI 0.685--0.741) in the training cohort and 0.746 (95% CI 0.625--0.867) in the validation cohort, suggesting that the nomogram was a good model for predicting outcomes. The calibration plot of the external validation cohort also showed good consistency between the actual and nomogram‐predicted OS (Fig [5](#tca13059-fig-0005){ref-type="fig"}).

![Nomogram for prediction of 5 and 10‐year overall survival.](TCA-10-1167-g003){#tca13059-fig-0003}

![Calibration curves of the nomogram‐predicted (**a**) 5‐year and (**b**) 10‐year overall survival in the training cohort.](TCA-10-1167-g004){#tca13059-fig-0004}

![Calibration curves of the nomogram‐predicted (**a**) 5‐year and (**b**) 10‐year overall survival in the validation cohort.](TCA-10-1167-g005){#tca13059-fig-0005}

Discussion {#tca13059-sec-0015}
==========

In this study, using \> 1000 cases from the SEER database, we showed that age, tumor size, Masaoka--Koga stage, chemotherapy, and surgery type were independent prognostic factors of OS and developed a nomogram to effectively visually predict the 5 and 10‐year OS rates of patients with thymomas.

The indolent natural history and excellent prognosis largely restricted the research to thymic epithelial tumors, especially thymomas. Surgical resection remains independently prognostic of improved survival.[12](#tca13059-bib-0012){ref-type="ref"}, [13](#tca13059-bib-0013){ref-type="ref"} Zhao *et al.* reported that complete resection improves disease‐free survival;[12](#tca13059-bib-0012){ref-type="ref"} however, the complex structure in the anterior mediastinum makes it difficult to completely resect tumors, particularly advanced‐stage tumors.[14](#tca13059-bib-0014){ref-type="ref"} Thus, multimodality treatment, including postoperative radiation and chemotherapy, has been adopted to prolong survival.

To enhance postsurgical tumor control and avoid locoregional recurrence, postoperative radiation is used in some institutions for radiosensitive thymomas, especially for incompletely resected tumors.[15](#tca13059-bib-0015){ref-type="ref"}, [16](#tca13059-bib-0016){ref-type="ref"} Postoperative radiation is recommended for completely resected stage III/IVA thymomas, but not for completely resected stage I thymomas because of their excellent prognosis.[17](#tca13059-bib-0017){ref-type="ref"}, [18](#tca13059-bib-0018){ref-type="ref"}, [19](#tca13059-bib-0019){ref-type="ref"} The use of postoperative radiation for stage II thymomas remains controversial. Jackson *et al.* demonstrated that younger age, early Masao--Koga stage, chemotherapy, and postoperative radiation were independently associated with longer OS in patients with thymomas.[14](#tca13059-bib-0014){ref-type="ref"} In contrast, we observed that postoperative radiation is not independently associated with longer OS. Consistent with the results of a Chinese study, we also observed that postoperative radiation is not an independent prognostic factor of OS.[20](#tca13059-bib-0020){ref-type="ref"}

Thus far, no randomized controlled trials assessing the effect of chemotherapy in thymomas have been conducted. In our study, chemotherapy was significantly associated with poor OS in thymomas. The European Society for Medical Oncology guidelines do not recommend administering chemotherapy after R0--R1 resection of a thymoma.[21](#tca13059-bib-0021){ref-type="ref"} For metastatic thymomas, chemotherapy is recommended.[22](#tca13059-bib-0022){ref-type="ref"}, [23](#tca13059-bib-0023){ref-type="ref"} Because stage III tumors cannot be distinguished from stage IV tumors in the SEER database, the current study did not explore the association between chemotherapy or postoperative radiation and metastatic thymomas.

There were several limitations to this study. First, retrospective studies are considered suboptimal compared to large randomized controlled trials. Second, the limitations of the SEER database prevented us from reaching a more precise result, as the database does not include variables to identify the sequence of surgery and chemotherapy or to elucidate the medications used in chemotherapy. Third, other factors may influence prognosis, such as surgical margin status, thus further research is needed to identify those prognostic factors and improve the nomogram.

Our results show that age, tumor size, Masaoka--Koga stage, chemotherapy, and surgery type are independent prognostic factors for OS in patients with thymomas. Furthermore, we developed a nomogram to effectively visually predict 5 and 10‐year OS in patients with thymomas.
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